Skip to main content
. 2017 Jun 30;8:731. doi: 10.3389/fimmu.2017.00731

Figure 2.

Figure 2

Combination antiretroviral therapy (cART) reverses T cell and monocyte activation, but not NK cell dysfunction or human CMV (HCMV) antibody levels. The proportion of FcRγ− NK cells (A), activated HLA-DR+CD38+ (B), and CD69+ (C) NK cells, plasma levels of HCMV-specific antibodies to either whole HCMV lysate (D) or gB antigen (E), the percentage of activated HLA-DR+CD38+ CD4+ (F) and CD8+ (G) T cells and the proportion of intermediate (CD14++CD16+) monocytes (H) was determined in HIV-uninfected MSM (n = 15) and HIV+ MSM (n = 20) at baseline (cART-naïve) and after 6, 12, and 24 months of cART. Graphs show median and IQR. +, ++, and ++++ denote p < 0.05, 0.01, and 0.0001, respectively, as compared to HIV− MSM determined by Mann–Whitney U test. *, **, and **** and denote p < 0.05, <0.01, and <0.0001, respectively, as compared to the corresponding cART-naïve value determined by Wilcoxon matched pairs signed rank test. AU, arbitrary units.